Clinical trial end points for high-grade glioma: the evolving landscape.
about
The three-layer concentric model of glioblastoma: cancer stem cells, microenvironmental regulation, and therapeutic implicationsMalignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methodsVirtual Raters for Reproducible and Objective Assessments in RadiologyMeningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO reviewResponse assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.Impact of neurocognitive deficits on patient-proxy agreement regarding health-related quality of life in low-grade glioma patients.Pros and cons of current brain tumor imagingOleanolic acid suppresses migration and invasion of malignant glioma cells by inactivating MAPK/ERK signaling pathwayChemotherapy-related changes in cognitive functioning.Dysregulation of Fra1 expression by Wnt/β-catenin signalling promotes glioma aggressiveness through epithelial-mesenchymal transition.The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients.MicroRNA expression signatures determine prognosis and survival in glioblastoma multiforme--a systematic overview.Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.CNS Anticancer Drug Discovery and Development Conference White Paper.Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials.Standards of care for treatment of recurrent glioblastoma--are we there yet?Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD)Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical EffectsEnzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation.Glioblastoma multiforme therapy and mechanisms of resistance.Chemotherapy-related cognitive dysfunction.Anti-angiogenic drug discovery: lessons from the past and thoughts for the future.Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.Relationship between cognitive function and prognosis in glioblastoma.Chemotherapy in glioma.Use of bevacizumab in recurrent glioblastoma.Alpinetin targets glioma stem cells by suppressing Notch pathway.Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level.Conditionally replicative adenovirus-based mda-7/IL-24 expression enhances sensitivity of colon cancer cells to 5-fluorouracil and doxorubicin.Use of positron emission tomography scanning to evaluate pseudoresponse.AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.Visual field changes as an early indicator of glioblastoma multiforme progression: two cases of functional vision changes before MRI detection.Assessment of intra-observer variability in measurement of high-grade brain tumors.MiRNA-mediated tumor specific delivery of TRAIL reduced glioma growth.Semiautomated volumetric measurement on postcontrast MR imaging for analysis of recurrent and residual disease in glioblastoma multiforme.Response Assessment in Neuro-Oncology Clinical Trials.Evidence and Context of Use for Contrast Enhancement as a Surrogate of Disease Burden and Treatment Response in Malignant Glioma.
P2860
Q26829663-4C5824D1-8809-4AF7-9C7E-35A985CFD75EQ26853516-111167F6-E08A-4F73-A39A-EECD4321B34AQ27318743-44F988E4-B1A4-4BDA-B707-BE592B1BC434Q30356126-C7892466-C19F-4946-9E40-A511623E7529Q30607148-416ADE34-28D8-4590-956B-41BF0888D681Q30840511-727F91D6-39B1-4C4D-83D4-24FD4F10582EQ30860126-D3239A7A-1094-445B-875A-1B9452A5CBADQ31132303-323EA490-F699-49D8-BD11-6128C1BF2C68Q33697950-3C4A429E-F5A6-47D7-A617-C79E42FAAF0AQ33792688-270B739F-5459-43D0-8865-6C9DA2CD3979Q34293163-822E8EF7-2C0B-4BF9-821B-346778D06631Q34409620-83EDABF0-1A2A-4BE4-BA97-412DDCA0F10EQ35914535-CC54191B-9BB0-484B-83F0-CCDBEB4E34C2Q36089590-4319FC63-8E4E-4DF9-AFE8-779B68386264Q36427538-B5113ECE-EA8E-4CAD-AF01-084530FFA898Q36500401-D3815847-0A45-4928-AF48-493B43BEF365Q36698172-EDDD4B23-93D7-4D2E-BCCB-261EFDE8DD0DQ36787777-198FC730-673F-43D8-8474-FC5111BE1601Q37132708-79AA8635-1BB9-4D32-B69A-4EC32322CDDAQ37187715-0FA44610-7DE7-4733-A414-507ED3111B7FQ37415954-BB91E68E-D155-4175-95CD-C20902B6D457Q37997653-C5B1EC12-CE7F-450C-A94B-AF0D326C47B2Q38020234-BABDF507-B587-4299-85DD-C8BA30961F5CQ38021521-31068271-D587-4BCF-B531-589A183430FFQ38062793-A1075BD7-037D-4DF3-B89F-FB40B4DFF352Q38068203-55B6BEB3-43AD-4A3D-9B00-DB761CC5FC86Q38233450-6EFDD1FE-83D8-4E77-8DAD-4195EC38E66FQ38438439-BD86652E-79E6-47BE-9FCF-A03771101AE7Q38438668-D92FD84E-70F6-4766-8369-073AC4FE9891Q38803548-04406B9C-A592-4DBE-975A-A47F129BA4A2Q38973191-94996A76-EC9E-4FBE-8186-5213BA60A7A7Q39310354-145CD16C-6EF9-48F9-8120-47B097225C98Q40033152-F47AF803-CBBA-4C9F-A4EE-C15D02C8A5A4Q41139015-AB2CEE1E-A17F-4BEF-B90E-90B8B8AD073AQ42429881-7C999EB6-8648-4104-B66E-CA62D21CEC31Q43932540-AD83715E-E1AE-440E-910E-E603ECA2F0DEQ44522644-1F4B9CBA-CB9A-4A3B-845F-A95176DDA480Q45124040-C1651E1C-B74C-4A64-8180-DB32BBDA8558Q45945655-C5FCC72B-CD11-466E-9D35-3AAAA58ED822Q47436703-89522A6E-6BB3-4BC6-AEA9-1C570B6F3F88
P2860
Clinical trial end points for high-grade glioma: the evolving landscape.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical trial end points for high-grade glioma: the evolving landscape.
@en
Clinical trial end points for high-grade glioma: the evolving landscape.
@nl
type
label
Clinical trial end points for high-grade glioma: the evolving landscape.
@en
Clinical trial end points for high-grade glioma: the evolving landscape.
@nl
prefLabel
Clinical trial end points for high-grade glioma: the evolving landscape.
@en
Clinical trial end points for high-grade glioma: the evolving landscape.
@nl
P2093
P2860
P50
P356
P1433
P1476
Clinical trial end points for high-grade glioma: the evolving landscape
@en
P2093
Andrew B Lassman
David A Reardon
David R Macdonald
Jeffrey S Wefel
John F DeGroot
Kathleen R Lamborn
Marc C Chamberlain
Mark R Gilbert
Michael A Vogelbaum
Patrick Y Wen
P2860
P304
P356
10.1093/NEUONC/NOQ203
P577
2011-02-09T00:00:00Z